Beating stem-cell derived cardiomyocytes The advent of iPS technology increases the utility of stem cell-derived experimental models, and negates many of the ethical concerns surrounding embryonic stem cells. [wpvideo PJJgsmYh] Human pluripotent stem cell (hPSC)-derived cardiomyocytes display normal cardiac characteristics, survive under cell culture conditions for extended periods and thus hold the potential to serve as a human-based model for both drug development and cardiotoxicity screening. The electrical activity and controllable environmental conditions of hPSCcardiomyocytes provide an ideal model for both drug development and toxicity testing. In addition to being useful for seeing changes in action potentials, hPSCcardiomyocytes are readily amenable to assessing toxic endpoints such as cell viability, apoptosis, ATP production/metabolism, and mitochondrial dysfunction through readily available test kits. In this article, the authors demonstrate the utility of hSC-derived cardiomyocytes for detecting apoptosis and cytotoxicity.
Video kindly provided by Cellular Dyanmics International, Inc.
Latest posts by Michele Arduengo (see all)
- Control Samples: Three Terrifying Tales for Scientists - October 31, 2018
- Forensic Scientists Improve Sexual Assault Kit Turnaround Time with Y-Screening - July 27, 2018
- Shaping the Future by Investing in Science - July 19, 2018